VEGFA and age-related macular degeneration: In this context, although anti-VEGF factor therapy is the first line of defense against neovascular AMD, anti-inflammatory agents such as corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), immunosuppressive agents (e.g., methotrexate and rapamycin), and biologics (e.g., infliximab, daclizumab, and complement inhibitors) may provide an adjunct or alternative mechanism to suppress the inflammatory processes in AMD.